Trial Outcomes & Findings for LIFT Intervention in Liver Transplant Candidates (NCT NCT04836923)

NCT ID: NCT04836923

Last Updated: 2026-05-15

Results Overview

Frailty is described as a biologic syndrome of decreased physiologic reserve and increased vulnerability to health stressors. This outcome is measured by the Liver frailty index \[LFI\]. LFI is composed of 3 performance-based tests (grip strength, chair stands, and balance). Patients are classified using established cutoffs (frail: LFI ≥ 4.5, pre-frail: LFI 3.3-4.4, robust: LFI ≤ 3.2). Higher LFI scores indicate a higher degree of frailty.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

81 participants

Primary outcome timeframe

Baseline and final frailty assessment (mean time from baseline to final frailty assessment was 216 (± 157) days)

Results posted on

2026-05-15

Participant Flow

The study team proposed to employ a "Realistic Effort Action Planning" (REAP) intervention, which is a form of personality-informed motivational interviewing, in a subset of patients to determine if this enhances the LIFT intervention. Due to funding and time restrictions, the study team was unable to employ this intervention and focused solely on the LIFT intervention. The record has been revised appropriately and these details have also been provided in the Limitations section.

Participant milestones

Participant milestones
Measure
LIFT Subgroup
PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members. "LIver FrailTy" intervention (LIFT): Novel physical therapy intervention to decrease frailty in pre-transplant patients
Overall Study
STARTED
81
Overall Study
COMPLETED
54
Overall Study
NOT COMPLETED
27

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

LIFT Intervention in Liver Transplant Candidates

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
LIFT Subgroup
n=54 Participants
PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members. "LIver FrailTy" intervention (LIFT): Novel physical therapy intervention to decrease frailty in pre-transplant patients
Comorbidities
Hyperlipidemia
8 Participants
n=11 Participants
Age, Continuous
57.2 years
STANDARD_DEVIATION 9.9 • n=11 Participants
Sex: Female, Male
Female
22 Participants
n=11 Participants
Sex: Female, Male
Male
32 Participants
n=11 Participants
Race/Ethnicity, Customized
White
47 Participants
n=11 Participants
Race/Ethnicity, Customized
Black
4 Participants
n=11 Participants
Race/Ethnicity, Customized
Hispanic
1 Participants
n=11 Participants
Race/Ethnicity, Customized
Asian
2 Participants
n=11 Participants
BMI
29.2 kg/m²
STANDARD_DEVIATION 5.9 • n=11 Participants
Comorbidities
Hypertension
10 Participants
n=11 Participants
Comorbidities
Diabetes Mellitus II
11 Participants
n=11 Participants
Comorbidities
Coronary Artery Disease
2 Participants
n=11 Participants
Comorbidities
Chronic Kidney Disease
3 Participants
n=11 Participants
Beta-blocker prescribed
11 Participants
n=11 Participants
Etiology of Liver Disease
Hepatitis C (HCV)
10 Participants
n=11 Participants
Etiology of Liver Disease
Alcohol-associated liver disease (ALD)
15 Participants
n=11 Participants
Etiology of Liver Disease
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
10 Participants
n=11 Participants
Etiology of Liver Disease
Autoimmune Hepatitis (AIH)
6 Participants
n=11 Participants
Etiology of Liver Disease
Other
13 Participants
n=11 Participants
Decompensated
Ascites
31 Participants
n=11 Participants
Decompensated
Hepatic encephalopathy
22 Participants
n=11 Participants
Decompensated
History of Variceal Bleeding
27 Participants
n=11 Participants
Decompensated
History of Spontaneous Bacterial Peritonitis
2 Participants
n=11 Participants
Decompensated
Hepatocellular Carcinoma
11 Participants
n=11 Participants
Model for End-Stage Liver Disease Sodium Score (MELD-Na)
16.9 units on a scale
STANDARD_DEVIATION 5.8 • n=11 Participants
Baseline Liver Frailty Index
3.63 units on a scale
STANDARD_DEVIATION 0.60 • n=11 Participants
Baseline Frailty Status by Liver Frailty Index
Robust (LFI ≤ 3.2)
14 Participants
n=11 Participants
Baseline Frailty Status by Liver Frailty Index
Pre-Frail (LFI 3.3-4.4)
23 Participants
n=11 Participants
Baseline Frailty Status by Liver Frailty Index
Frail (LFI ≥ 4.5)
17 Participants
n=11 Participants
Baseline Patient-Reported Physical Function T-score
46.6 units on a scale
STANDARD_DEVIATION 8.3 • n=11 Participants

PRIMARY outcome

Timeframe: Baseline and final frailty assessment (mean time from baseline to final frailty assessment was 216 (± 157) days)

Frailty is described as a biologic syndrome of decreased physiologic reserve and increased vulnerability to health stressors. This outcome is measured by the Liver frailty index \[LFI\]. LFI is composed of 3 performance-based tests (grip strength, chair stands, and balance). Patients are classified using established cutoffs (frail: LFI ≥ 4.5, pre-frail: LFI 3.3-4.4, robust: LFI ≤ 3.2). Higher LFI scores indicate a higher degree of frailty.

Outcome measures

Outcome measures
Measure
LIFT Subgroup
n=54 Participants
PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members. "LIver FrailTy" intervention (LIFT): Novel physical therapy intervention to decrease frailty in pre-transplant patients
Frailty
Baseline
3.63 score on a scale
Standard Deviation 0.60
Frailty
Post-Intervention
3.48 score on a scale
Standard Deviation 0.68

PRIMARY outcome

Timeframe: Baseline and final frailty assessment (mean time from baseline to final frailty assessment was 216 (± 157) days)

Patient-reported physical quality of life was measured using a validated patient-reported outcome measure (Patient-Reported Outcomes Measurement Information System Physical Function \[PROMIS-PF\]) completed in clinic. Patient-reported physical function was measured using a validated patient-reported outcome measure: Patient-Reported Outcomes Measurement Information System Physical Function \[PROMIS-PF\] Version 2.0 - Short Form 8c. A higher PROMIS T-score represents more of the concept being measured. A score of 50 is the average for the United States general population with a standard deviation of 10. A Physical Function T-score of 60 is one SD better than average. By comparison, a Physical Function T-score of 40 is one SD worse than average. Physical Function T-Scores range from 20.3 to 60.1.

Outcome measures

Outcome measures
Measure
LIFT Subgroup
n=54 Participants
PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members. "LIver FrailTy" intervention (LIFT): Novel physical therapy intervention to decrease frailty in pre-transplant patients
Patient-reported Physical Function
Post-Intervention
46.7 score on a scale
Standard Deviation 7.9
Patient-reported Physical Function
Baseline
46.6 score on a scale
Standard Deviation 8.3

PRIMARY outcome

Timeframe: 1 month and 3 months after Enrollment, throughout the follow-up period (mean follow-up time is 259 (±190) days)

Data continuously collected via TrueCoach smart phone application to document adherence to exercise regimen. If patients are unable to appropriately track adherence on the smart phone application, this data will be collected at weekly videoconference/telephone check-ins detailed below. Exercise adherence rates are defined as the number of completed or attempted exercise days/total exercise days prescribed. Overall, patients were classified as adherent to the exercise regimen if their adherence rate was ≥ 75% and partially adherent if ≥ 50%. Patients were classified as non-adherent if their adherence rate was \< 50%. The mean intervention rate was measured throughout the follow-up period (from enrollment to final assessment) - the mean follow-up time was 259 (±190) days.

Outcome measures

Outcome measures
Measure
LIFT Subgroup
n=54 Participants
PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members. "LIver FrailTy" intervention (LIFT): Novel physical therapy intervention to decrease frailty in pre-transplant patients
Exercise Adherence Rate
1-month adherence rate (after enrollment)
62 percentage of exercise adherence
Interval 0.0 to 100.0
Exercise Adherence Rate
3-month adherence rate (after enrollment)
60 percentage of exercise adherence
Interval 0.0 to 100.0
Exercise Adherence Rate
Mean Intervention adherence rate (throughout follow-up period, mean follow-up time was 259 days)
51 percentage of exercise adherence
Interval 0.0 to 100.0

SECONDARY outcome

Timeframe: Throughout the follow-up period (mean follow-up time is 259 (±190) days)

Population: No new liver related complications (e.g., new episodes of variceal bleeding) were reported because of the LIFT intervention during the follow-up period.

Data collected from medical chart for liver related complications including but not limited to diagnosis of: ascites, hepatic encephalopathy, variceal bleeding, hepatorenal syndrome, hepatopulmonary syndrome, infection.

Outcome measures

Outcome measures
Measure
LIFT Subgroup
n=54 Participants
PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members. "LIver FrailTy" intervention (LIFT): Novel physical therapy intervention to decrease frailty in pre-transplant patients
Clinical Outcomes - Liver Related Complications
No new episodes of liver related complications
54 Participants
Clinical Outcomes - Liver Related Complications
New episodes of liver related complications
0 Participants

Adverse Events

LIFT Subgroup

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Therese Banea

Northwestern University

Phone: 312-694-7993

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place